James Rolke - 03 Feb 2026 Form 4 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Role
Chief Executive Officer, Director
Signature
/s/ J.P. Galda, as attorney-in-fact for James Rolke
Issuer symbol
REVB
Transactions as of
03 Feb 2026
Net transactions value
-$15,849
Form type
4
Filing time
05 Feb 2026, 17:29:45 UTC
Previous filing
12 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rolke James Chief Executive Officer, Director C/O REVELATION BIOSCIENCES, INC., 4660 LA JOLLA VILLAGE DR., SUITE 100, SAN DIEGO /s/ J.P. Galda, as attorney-in-fact for James Rolke 05 Feb 2026 0001693858

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REVB Common Stock Tax liability $15,849 -8,521 -3.7% $1.86 224,853 03 Feb 2026 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
F2 Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.